Benzinga's Top #PreMarket Losers

Onconova Therapeutics (NASDAQ: ONTX ) shares fell 41.20% to $8.15 in the pre-market trading after the company announced results from Phase 3 ONTIME Trial of Rigosertib in higher risk myelodysplastic syndromes. Piper Jaffray downgraded the stock from Overweight to Neutral and lowered the price target from $38.00 to $9.00. Conns